Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110661 | 0.87 | MAPKAPK2 (0.41) | MAPKAPK2TGFBR1MAPTPAK4MKNK1 | |
| SCHEMBL29543341 | 0.82 | MAPKAPK2 (0.37) | MAPKAPK2NOS1PAK4MKNK1ADORA3 | |
| SCHEMBL18196425 | 0.82 | MAPKAPK2 (0.37) | MAPKAPK2NOS1PAK4MKNK1ADORA3 | |
| SCHEMBL29542999 | 0.80 | MAPKAPK2 (0.39) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL18188133 | 0.80 | MAPKAPK2 (0.39) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL18196421 | 0.72 | TRPA1 (0.43) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL29543346 | 0.72 | MAPKAPK2 (0.37) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL29543046 | 0.72 | TRPA1 (0.43) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL18188697 | 0.72 | MAPKAPK2 (0.37) | MAPKAPK2MAPTPAK4MKNK1ADORA3 | |
| SCHEMBL10213601 | 0.72 | MAPKAPK2 (0.73) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | MAPKAPK2 2947/4885NOS1 530/4885TGFBR1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.